## Allergen Specific IgE

	Anergen opeenteige		
Accreditation Status:	UKAS Schedule of Accreditation		
Date Scheme started:	1988		
Clinical Applicability:	Diagnosis and management of allergic disease		
Analytes:	<b>(SER/032)</b> The programme includes the assessment of common or clinically important, individual IgE specificities, for example:		
	D1Dermatophagoides pteronyssinus E1 Cat epitheliumE5Dog danderF1Egg whiteF2Cow's milkF13PeanutF17Hazel nutG6Timothy grassI1Bee venomI3Wasp venomK82Latex		
	K82 Latex M3 Aspergillus fumigatus M6		
	Alternaria alternata		
	T3 Birch		
	W6 Mugwort		
	Other allergen specificities may be included, subject to the availability of clinically validated donor serum units		
Units for Reporting:	Grade and kU/L (arbitrary)		
Samples Distributed:	Liquid format. Normal and pathological human		
Number of Distributions per year:	6		
Number of Samples per Distribution:	2		
Frequency of Distributions:	Every two months as outlined in the <b>Distribution Schedule.</b> Four allergen specific IgE tests will be analysed on each specimen		
Schedule of Analysis:	<b>Data entry</b> is via the web for the submission of results. Data analysis is commenced 21 days after sample dispatch. Late returns are accepted and will contribute to the laboratory's cumulative performance statistics		
Data Analysis:	Analysis by grade shows the overall response and the method specific responses. Analysis of the quantitative responses in Units shows the All Laboratory Trimmed Mean (ALTM) with truncation at 2SD, SD and CV%. Reports show method specific statistics. Individual laboratory performance is expressed in terms of MRBIS, SDBIS and MRVIS, the DV for calculation of VI being taken from the MLTM		
	Chosen Coefficient of Variation for Allergen Specific IgE is 12%		
Performance Scoring:	Cumulative performance scores are based on the quantitative response with MRVIS scoring over a running window of twelve samples or twelve months		
Criteria of Performance:	Performance assessment is allergen specific. Quantitative performance is assessed for each allergen, and is over a running period of 6 distributions		

## containing that allergen (12 months)

Ideal	MRVIS	<50
Good		50 - 100
Adequate		101 - 200
Poor		>200 or SDBIS >200

The overall quantitative performance is expressed as the OMRVIS, the mean of all the individual allergen specific MRVIS

The semiquantitative Grades are assessed by MI scoring in relation to the Consensus Designated Response (CONDR). (For this purpose, Grades 2-6 are considered as CLEAR POSITIVE)

Good	OMIS	Zero
Adequate		1 - 3
Poor		>4

Overall MIS (OMIS) greater than 4 will also be considered as poor performance

**Persistent Poor Performance:** 

Defined as being in the Poor Performance category for two or more successive distributions